A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum-Based Agents Using the FDA...

Area of Science:

• Oncology
• Pharmacovigilance
• Clinical Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy are standard treatments for various cancers.
• Understanding the adverse event (AE) profile of this combination therapy is critical for patient safety.

Purpose of the Study:

• To analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum-based compounds.
• To identify specific safety signals and patterns of toxicity using real-world data.

Main Methods:

• Retrospective analysis of AE data from the FDA Adverse Event Reporting System (FAERS) database (2008-2024).
• Utilized multiple disproportionality analysis algorithms, including ROR, PRR, BCPNN, and MGPS, to detect safety signals.
• Analyzed 28,585 reports to identify significant adverse event signals.

Main Results:

• Identified 27 significant SOC-level signals, with notable associations for hematological, endocrine, and hepatobiliary disorders.
• Key identified adverse events included malignant neoplasm progression, febrile neutropenia, and myocarditis.
• AEs often occurred early (median onset: 38 days), with higher rates of neurotoxicity compared to monotherapy, although malignancy progression and nephrotoxicity were lower.

Conclusions:

• The combination therapy presents distinct early-onset toxicities and novel risks such as neuropathy, myocarditis, and leukemia.
• Enhanced initial monitoring and subgroup-specific management strategies are necessary for patients receiving this combination treatment.
• The findings highlight the importance of pharmacovigilance in optimizing cancer treatment regimens.